Aptus Pharma (544529) Stock Overview

Engages in the marketing and distribution of finished pharmaceutical formulations. More details

544529 fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	4/6
Financial Health	4/6
Dividends	0/6

Rewards

Price-To-Earnings ratio (27.5x) is below the Indian market (27.8x)

Earnings grew by 260.5% over the past year

Risk Analysis

Shares are highly illiquid

High level of non-cash earnings

Debt is not well covered by operating cash flow

Does not have a meaningful market cap (₹854M)

+ 1 more risk

544529 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

Aptus Pharma Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for Aptus Pharma
Historical stock prices
Current Share Price	₹124.46
52 Week High	₹139.99
52 Week Low	₹80.80
Beta	0
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	46.70%

Recent updates

Shareholder Returns

	544529	IN Healthcare	IN Market
7D	18.9%	2.5%	2.3%
1Y	n/a	30.4%	1.5%

Return vs Industry: Insufficient data to determine how 544529 performed against the Indian Healthcare industry.

Return vs Market: Insufficient data to determine how 544529 performed against the Indian Market.

Price Volatility

Is 544529's price volatile compared to industry and market?
544529 volatility
544529 Average Weekly Movement	n/a
Healthcare Industry Average Movement	4.9%
Market Average Movement	5.2%
10% most volatile stocks in IN Market	8.4%
10% least volatile stocks in IN Market	3.2%

Stable Share Price: 544529's share price has been volatile over the past 3 months compared to the Indian market.

Volatility Over Time: Insufficient data to determine 544529's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2010	70	Ghanshyam Pansuriya	aptus-pharma.com

Aptus Pharma Limited engages in the marketing and distribution of finished pharmaceutical formulations. The company operates through four divisions: Aptus Pharma, Pioneer division which includes marketing of acute therapies including general anti-infectives, pain management, antacids, and gastrointestinal drugs; Aptus CD Care, Cardiac Diabetic division which includes marketing of chronic therapies, including anti-hypertensive, anti-diabetic, and lipid-lowering; Aptus Wellcare offers wellness and nutraceutical products, over-the-counter (OTC) formulations, and personal care products; and Aptus Global, export division engages in exploring and developing opportunities in overseas markets, semi-regulated and emerging countries. It also offers anti-infectives, gastrointestinal, antacids, anti-allergic and respiratory, nutritional supplements, pain management, neuro-psychiatric, cardiovascular, antidiabetic, lipid-lowering, and general wellness products.

Aptus Pharma Limited Fundamentals Summary

How do Aptus Pharma's earnings and revenue compare to its market cap?
544529 fundamental statistics
Market cap	₹853.80m
Earnings (TTM)	₹31.00m
Revenue (TTM)	₹245.58m

27.5x

P/E Ratio

3.5x

P/S Ratio

Is 544529 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
544529 income statement (TTM)
Revenue	₹245.58m
Cost of Revenue	₹90.37m
Gross Profit	₹155.21m
Other Expenses	₹124.21m
Earnings	₹31.00m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	4.52
Gross Margin	63.20%
Net Profit Margin	12.62%
Debt/Equity Ratio	148.7%

How did 544529 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/10/22 21:41
End of Day Share Price	2025/10/21 00:00
Earnings	2025/03/31
Annual Earnings	2025/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Aptus Pharma Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Aptus Pharma LimitedBSE:544529 Stock Report